An Evaluation of a Factor Xa-Based Clotting Time Test for Enoxaparin: A Proof-of-Concept Study by Ng, Deborah P. J. et al.
Original Article
An Evaluation of a Factor Xa-Based
Clotting Time Test for Enoxaparin:
A Proof-of-Concept Study
Deborah P. J. Ng, BPharm1,2, Stephen B. Duffull, PhD2, James M. Faed, FRCPA3,
Geoffrey K. Isbister, MD4, and Abhishek Gulati, PhD2,5,6
Abstract
A well-accepted test for monitoring anticoagulation by enoxaparin is not currently available. As inadequate dosing may result in
thrombosis or bleeding, a clinical need exists for a suitable test. Previous in silico and in vitro studies have identified factor Xa as an
appropriate activating agent, and the phospholipid Actin FS as a cofactor for a Xa clotting time (TenaCT) test. A proof-of-concept
study was designed to (1) explore the reproducibility of the TenaCT test and (2) explore factors that could affect the performance
of the test. In vitro clotting time tests were carried out using plasma from 20 healthy volunteers. The effect of enoxaparin was
determined at concentrations of 0.25, 0.50, and 1.0 IU/mL. Clotting times for the volunteers were significantly prolonged with
increasing enoxaparin concentrations. Clotting times were significantly shortened for frozen plasma samples. No significant
differences in prolongation of clotting times were observed between male and female volunteers or between the 2 evaluated age
groups. The clotting times were consistent between 2 separate occasions. The TenaCT test was able to distinguish between the
subtherapeutic and therapeutic concentrations of enoxaparin. Plasma should not be frozen prior to performing the test, without
defining a frozen plasma reference range. This study provided proof-of-concept for a Xa-based test that can detect enoxaparin
dose effects, but additional studies are needed to further develop the test.
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Introduction
Thrombosis is the pathological formation of a blood clot within
blood vessels. It occurs as a result of activation of the platelet-
coagulation system and depending on the pathological process
will lead to formation of an arterial or venous thrombus.1
Thrombi are most commonly manifested clinically in the acute
coronary syndrome (ACS) or as venous thromboembolism
(VTE). Data produced by the Centers for Disease Control and
Prevention in 2015 estimated the overall annual incidence of
VTE in the United States to be between 1 and 2 per 1000 of the
population.2,3 Thrombosis is usually treated with anticoagu-
lants (unfractionated heparin [UFH], low-molecular-weight
heparins [LMWHs]), antiplatelet agents [aspirin, ticlopidine],
or for selected conditions with high-morbidity fibrinolytics
[streptokinase, alteplase]).1 It is appropriately important to
dose anticoagulants as bleeding may occur from excessive
doses or thrombosis from inadequate doses.
Enoxaparin is an LMWH anticoagulant that increases the
activity of a physiological inhibitor, antithrombin.1,4 This
results in increased inhibitory action of antithrombin on coa-
gulation factors, factor Xa in particular, thus prolonging the
time to form a fibrin clot. Despite claims that enoxaparin
therapy does not need monitoring due to the reportedly pre-
dictable dose–response relationship; many studies have shown
that enoxaparin has similar bleeding rates as UFH.4 In a study
carried out in 2005, out of 446 non-ST-elevated ACS admis-
sions that received enoxaparin, major bleeding (eg, retroperi-
toneal bleeding, intracranial bleeding) occurred in 1.8% of
these patients and minor bleeding in 8.7%.5 Many studies have
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therefore stressed the point of monitoring enoxaparin
therapy.5,6
Prothrombin time (PT), usually reported as an international
normalized ratio, and activated partial thromboplastin time
(aPTT) tests are used to monitor the anticoagulant effects of
warfarin and UFH, respectively. These clotting time (CT) tests
have been shown to provide a good prediction of bleeding and
thrombosis when used with warfarin and UFH. On the other
hand, no well-accepted method exists for monitoring the antic-
oagulation effect of enoxaparin or other LMWHs. Both PT/
INR and aPTT do not show significant dose–response changes
with enoxaparin4 and are therefore not suitable for measuring
the effect of enoxaparin. Indirect measurement of anti-Xa
activity using a chromogenic assay has been shown to correlate
with the effect of enoxaparin, but a well-accepted target activ-
ity value is not available and dose adjustments are difficult to
make.4,7,8 In addition, these anti-Xa assays measure the activity
of a single coagulation factor Xa which corresponds to enox-
aparin concentration only, as compared to CT tests (such as PT
and aPTT) that consider the activity of wider activity in the
integrated coagulation network. Hence, a deficiency in a reg-
ulatory coagulation factor (eg, antithrombin) may affect clot-
ting ability but would not have an effect in a standard anti-Xa
test. We propose that a CT test that assesses wider coagulation
activity would be of more value.
Previous attempts at developing CT tests for LMWHs
include 3 Xa-based tests. However, they are not widely used
clinically for LMWH testing and have limitations. StaClot
(product of Diagnostica Stago, Asnie`res-sur-Seine, France) and
HepTest (product of American Diagnostica Inc, Stamford, CT,
USA) appear to have been designed to identify the anti-Xa
concentration present in the sample, rather than determining
the net anticoagulant effect which is likely to be clinically more
relevant in terms of bleeding and clotting risk. The third Xa-
based CT test that currently exists is the Xa-activated CT test
which is a whole blood coagulation assay. Platelets play a
major role in blood coagulation, and the main limitation of this
test is the presence of platelets which may cause the behavior of
the test to be significantly different compared to clinically used
CT tests that use plasma samples.
Factor Xa was identified as a suitable activating agent for
the development of a CT test for enoxaparin based on a recent
in silico study using a mathematical model of the coagulation
network and a corresponding in vitro evaluation in a single
healthy volunteer.9 The activation of Xa provides an appropri-
ate point for evaluating the overall impact of enoxaparin in a
rapid assay. The assay would avoid the limitations imposed on
direct factor Xa inhibition assays (eg, a chromogenic assay for
Xa). Subsequent in vitro evaluation in an adaptive design
cohort study of 6 healthy volunteers identified phospholipid
Actin FS as a useful stabilizing cofactor for this Xa-based
clotting time test (TenaCT test).10 The TenaCT test accounts
for the variability in the coagulation factors and reflects the
activity of the coagulation network. Actin FS is a commercially
available aPTT reagent consisting of purified soy phosphatides
(as the phospholipid component) and ellagic acid activator (as
the activating agent in the commercially available aPTT test)
and was included in order to determine the net anticoagulant
effect of LMWHs. The phospholipid component was not avail-
able as a single product; the presence of ellagic acid at the
concentrations used is considered to have had negligible effects
in the assays performed. In future evaluation of the test, the
phospholipid (purified soy phosphatides) per se will be further
investigated at a range of concentrations. In this work, we
explore these reagents in a clotting time test (TenaCT test) in
a larger cohort of healthy volunteers.
Specifically, this study was a proof-of-concept study
designed to:
1. explore the reproducibility of the TenaCT test and
2. explore factors that could affect the performance of the
TenaCT test
The factors chosen were (a) gender—to detect gender-
specific differences in the CT using plasma from male and
female healthy volunteers; (b) age—to detect age-specific dif-
ferences in the CT using plasma from volunteers of different
age groups; and (c) freezing the plasma samples—to explore if
the freeze–thaw process affects the performance of the test. (d)
The test was also performed using plasma obtained from the




FactorXa (catalytic activity¼ 71 nkat) was sourced fromAbacus
ALS Limited, Auckland, New Zealand, a supplier of Chromo-
genix products. Commercial enoxaparinwas available as clexane
injection (2000 IU/0.2 mL), manufactured by Sanofi Aventis,
Paris, France. Cofactor Actin FS was purchased from Siemens
HealthcareDiagnostics Ltd, Auckland, NewZealand. In vitroCT
experiments were carried out using STart hemostasis analyzer, a
product of Diagnostica Stago Pty Ltd, Doncaster, Australia.
Methods
Recruitment of Volunteers
Healthy adult volunteers (n ¼ 20) aged between 18 and 50
years were recruited from staff and students at the University
of Otago, Dunedin, New Zealand. The number of healthy
volunteers was arbitrarily chosen for an initial evaluation.
Future investigations will evaluate the test in a higher number
of volunteers. Applicants were excluded if they had at the time
of recruitment or in the previous month:
 An inflammatory condition as a result of physical injury
or immunological disorder (eg, sprain, asthma, arthritis,
etc) or an infection;
 Taken any prescription medicine that could suppress or
treat an inflammatory response or that is known to affect
CT or bleeding time;
670 Clinical and Applied Thrombosis/Hemostasis 24(4)
 Had a recent visit to the dentist: fillings or scaling within
7 days, or extractions, gingival, and other invasive pro-
cedures within 21 days; and
 Been pregnant, breast-feeding, or were taking hormonal
treatments including oral contraceptives.
This study was approved by the University of Otago human
ethics committee. Table 1 summarizes the demographics for
the participants enrolled in the study.
Blood Collection and Storage
Blood collection for this study was done by trained phleboto-
mists at the Blood Collection Centre, Dunedin Hospital, New
Zealand. Blood was obtained from the volunteers on 2 separate
occasions, at least 14 days apart. On each occasion, 30 mL of
blood was obtained in citrated polystyrene tubes and was cen-
trifuged at 2000g for 20 minutes at 20C. This was performed
twice to obtain platelet-free plasma. Any other method utilizing
different time duration, temperature, or speed of centrifugation
could have been used as well, as far as platelet-free plasma
could be obtained. The plasma obtained was divided into 2
parts of equal volumes (see Figure 1):
 the first part (referred to as “fresh plasma”) was used to
carry out the in vitro CT experiments immediately on the
same day and
 the second part (referred to as “frozen plasma”) was
snap frozen and stored at 80C for repetition of the
experiments after at least 24 hours in a single freeze–
thaw cycle.
In Vitro CT Test Experiments
The in vitro CT tests were carried out using a STart hemostasis
analyzer, which utilizes a viscosity-based detection system.
Concentrations of Xa and Actin FS used in this study were
based on a previous study10 and were equal to 20 nM and
0.17%, respectively.
A 200 mL mixture of equal volumes of Xa (20 nM) and
CaCl2 (25 mM) was incubated at 37
C and added to 100 mL of
plasma, which was prewarmed at 37C. The time taken for the
clot to form was recorded. The CT was then determined in the
presence of various concentrations of enoxaparin (0 [control],
0.25, 0.50, and 1.0 IU/mL). The healthy volunteers were not
being dosed with enoxaparin. Plasma samples were spiked
with enoxaparin by adding 1 part of enoxaparin to 9 parts of
plasma. The CT experiments were then carried out in the
presence of the cofactor Actin FS. The activator solution in
this case consisted of equal volumes of: a mixture of Xa (20
nM) and Actin FS (0.17%) and CaCl2 (25 mM). All CT
measurements were performed in triplicate, and the
results reported as mean (standard deviation [SD]). The
increases in CTs were compared among the following groups
to assess the factors that affect the performance of the Xa-
based clotting time test:
 CTs of fresh versus frozen plasma samples;
 CTs of male versus female plasma;
 CTs of plasma from volunteers aged 18 to 33 years
versus those 34 to 50 years; and
 CTs of plasma obtained on 2 different occasions at least
14 days apart.
The evaluation of gender and age as potential factors that
could affect the performance of the test was initially carried out
using a small sample size of n ¼ 10, which was arbitrarily
chosen. Future investigations will be carried out using a larger
number of male and female healthy volunteers as well as using
plasma from volunteers aged older than 50 years. Figure 1
shows the schematic of the experimental design for the in vitro
CT test experiments.
The most widely available test for monitoring of antifactor
Xa activity of LMWHs is a chromogenic assay and is the test
currently recommended by the College of American Patholo-
gists.11 Anti-Xa activity has been shown to be inversely related
to thrombus propagation and the development of an occlusive
thrombosis,12,13 but the minimum effective level remains
uncertain. In addition, a single factor inhibition assay will not
detect the effect of other factors and inhibitors such as antith-
rombin. Currently, a therapeutic range for peak effect with
twice daily administration of enoxaparin is 0.50 to 1.0 IU/mL
and is used for patients being treated for acute VTE.11,14-16 The
performance of the TenaCT test was therefore assessed in the
presence of subtherapeutic and therapeutic enoxaparin concen-
trations. Among the concentrations of enoxaparin used in this
study, control (0 IU/mL) and 0.25 IU/mL were considered as
subtherapeutic concentrations and were compared to 0.50 and
1.0 IU/mL as therapeutic enoxaparin concentrations,
respectively.
Statistical Analysis
Clotting times for individual volunteers were measured in sec-
onds and data reported as mean (SD). The mean CT for the
population of 20 volunteers was also reported along with the
95% confidence interval (CI) of the mean. A paired t test was
used to evaluate the difference in ratio of the TenaCT in the
absence and presence of Actin FS and between fresh and frozen
plasma samples. An unpaired t test was used to evaluate the
ratio of the TenaCT with and without various enoxaparin
Table 1. Demographics of the Study Volunteers.
Number of Volunteers
Total participants enrolled 20
Male participants 10
Aged between 18 and 33 years (range) 5 (24-27 years)
Aged between 34 and 50 years (range) 5 (34-46 years)
Female participants 10
Aged between 18 and 33 years (range) 5 (22-32 years)
Aged between 34 and 50 years (range) 5 (36-38 years)
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concentrations, the difference in TenaCT times for individual
donors and the various groups: plasma from males versus
females, volunteers 18 to 33 years versus those 34 to 50 years,
and plasma from volunteers obtained at 2 different occasions at
least 14 days apart. Level of significance was set at P < .05. The
analysis was carried out using the software GraphPad Prism
version 6.05.
Criterion for a Successful CT Test
A CT test in an individual volunteer at a single occasion
was said to be successful if each of the following conditions
were met:
1. The CT for a control plasma sample was between 10
and 30 seconds.
2. The CTs increased with increasing enoxaparin
concentrations.
3. The prolongation of CTs at enoxaparin concentration of
1.0 IU/mL should be greater than 3 times the control
plasma sample.
4. The CTs should not be more than 180 seconds to ensure
rapid turnaround of test results.
Success in a volunteer was defined as when all of the con-
ditions were true (ie, the criterion was met) with both plasma
samples for each volunteer.
Results
The reproducibility of the Xa-based clotting time test was
assessed in 20 healthy volunteers at various enoxaparin con-
centrations. In the presence of the cofactor Actin FS, the CTs
for the majority of the volunteers were within the measurable
range. Only 1 volunteer exceeded 200 seconds, the upper limit
for STart Hemostasis Analyzer, at an enoxaparin concentration
of 1.0 IU/mL. In the absence of Actin FS, however, CTs in
majority of the volunteers were not measurable (>200 seconds)
at the highest enoxaparin concentration of 1.0 IU/mL. There
were only 4 occasions where the CT test met the criterion, and
there was no volunteer for whom the test was deemed success-
ful, that is, the criterion was met on both of the volunteer’s test
samples. Table 2 summarizes the results with times less than
200 seconds in the absence or presence of Actin FS. The
coefficient of variation (CV)% for all CT test experiments
ranged between 0.14% and 3.38%, showing good reproduci-
bility of test performance.
1. Evaluation of the performance of the TenaCT test based
on the criterion for a successful CT test:
a. Condition 1 (CTs for control plasma should lie
between 10 and 30 seconds)
Clotting times for both occasions for all patients were within
the range of 10 to 30 seconds, except for 1 occasion where the
mean CT slightly exceeded the upper limit at a value of 31
seconds.
b. Condition 2 (CTs should increase at increasing
enoxaparin concentrations)
The mean CTs for the control plasma group (n ¼ 20) at
the first occasion was 17 + 4.2 seconds (95% CI: 15-19
seconds). The mean CTs significantly increased (P < .05)
with an increase in enoxaparin concentration to 26 + 11
seconds at 0.25 IU/mL (95% CI: 21-31 seconds, n ¼ 20),
42 + 20 seconds at 0.50 IU/mL (95% CI: 32-51 seconds,
n ¼ 20), and 81 + 39 seconds at 1.0 IU/mL (95% CI: 62-
100 seconds, n ¼ 19). With increasing enoxaparin concen-
trations, the mean CTs increased progressively, as shown in
Figure 2A. This shows that the TenaCT test was able to
distinguish the effect of varying concentrations of enoxa-
parin using a plasma CT test.
Similar trends were observed with the plasma samples col-
lected from the volunteers at the second occasion. The mean
CTs for the control plasma group (n ¼ 20) was 16 + 1.3
seconds (95% CI: 15-16 seconds) which increased to 24 +
3.2 seconds (95% CI: 22-25 seconds, n ¼ 20) at an enoxaparin
Figure 1. Schematic of the experimental design for the in vitro clotting
time test experiments.





Number of volunteers who meet the criterion 0 14
Number of occasions that meet the criterion 4 33
aTotal number of volunteers were equal to 20, each for “without Actin FS” and
“with Actin FS” groups.
bTotal number of occasions were equal to 40, each for “without Actin FS” and
“with Actin FS” groups.
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concentration of 0.25 IU/mL, 37 + 9.3 seconds (95% CI:
33-41 seconds, n ¼ 20) at an enoxaparin concentration of
0.50 IU/mL, and 82 + 37 seconds (95% CI: 64-99 seconds,
n ¼ 19) at an enoxaparin concentration of 1.0 IU/mL. These
differences in the CTs at different enoxaparin concentrations
were significant (P < .05), as shown in Figure 2B. The wide
range observed at each LMWH concentration indicates varying
sensitivity of each volunteer’s plasma to LMWH.
c. Condition 3 (prolongation of CTs in the presence of
1 IU/mL enoxaparin should be at least 3 times higher
than the control group)
Mean prolongation of TenaCT at an enoxaparin concentra-
tion of 1.0 IU/mL compared to the control was greater than 3
times at both the occasions (n¼ 18 for each occasion).Mean fold
prolongation in TenaCTat the first occasionwas 4.8+ 1.7 (95%
CI: 3.9-5.6) compared to 5.1 + 2.1 (95% CI: 4.1-6.1) at the
second occasion. The CTs for the 2 occasions were not statisti-
cally different (P¼ .54). The results are summarized in Figure 3.
d. Condition 4 (all CTs should be <180 seconds)
TenaCT at all enoxaparin concentrations was less than 180
seconds on all but 4 samples. The upper limit for CTs on the
STart Hemostasis Analyzer can be adjusted and for the period
of this study was set at 200 seconds.
2. Evaluation of the performance of the TenaCT test at
subtherapeutic versus the therapeutic enoxaparin
concentrations:
The reported therapeutic concentration for enoxaparin is
0.50 to 1.0 IU/mL. Prolongations in CTs of each sample at
each concentration of enoxaparin were compared with the
control samples. The first set of samples from volunteers at
an enoxaparin concentration of 0.25 IU/mL, resulted in a mean
fold prolongation in TenaCT of 1.5 + 0.19 (95% CI: 1.4-1.6,
n ¼ 20). This prolongation was significantly different (P < .05)
from that in the presence of 0.50 IU/mL (2.4+ 0.62, 95% CI:
2.1-2.7, n ¼ 20) and 1.0 IU/mL (4.8 + 1.7, 95% CI: 3.9-5.6,
n ¼ 19) enoxaparin. These were also significantly different
from the control group (P < .05). A similar ability to distinguish
subtherapeutic from therapeutic concetrations of enoxaparin
was seen with the second set of samples from each volunteer.
3. Evaluation of the factors that could affect the perfor-
mance of the TenaCT test:
a. Clotting times in fresh versus frozen plasma
samples
Significant differences in CTs were observed between fresh
and frozen plasma samples at all concentrations of enoxaparin
(P < .05). The mean fold prolongations in CTs at enoxaparin
concentration of 0.25, 0.50, and 1.0 IU/mL for frozen plasma
were 1.3 + 0.13, 1.7 + 0.26, and 2.6 + 0.60, respectively.
Clotting time test experiments for frozen plasma samples, after
a single freeze–thaw cycle, were stopped after 10 volunteers as
large differences between the CTs of fresh and frozen plasma
samples were observed, with significantly shorter CTs from
frozen-thawed plasma. It was concluded that plasma should
Figure 2. TenaCTs (in seconds) in the absence (control) or presence of enoxaparin concentrations of 0.25, 0.50, and 1.0 IU/mL at the (A) first
and (B) second occasions. Mean TenaCT for each individual volunteer is represented by a circle. The bars represent the mean TenaCT and the
95% confidence interval for the population of 20 volunteers. * denotes the level of significance at P < .05.
Figure 3. Fold prolongations in TenaCT in the presence of enoxa-
parin concentration of 1.0 IU/mL compared to the control (enoxa-
parin absent) at first versus the second occasions. Solid lines connect
the fold prolongations for each individual volunteer at occasions 1 and
2. Dashed line represents the 3-fold prolongation criterion.
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not be frozen prior to performing the TenaCT test without
determining a reference range for frozen normal samples. The
CTs obtained for each volunteer at all enoxaparin concentra-
tions with fresh as well as frozen plasma are presented as part
of the Supplementary Table 1.
b. Clotting times in male versus female volunteers
The fold prolongations in Xa CTs in the absence and pres-
ence of enoxaparin were not different between male and female
volunteers (P > .05). This was observed at all enoxaparin con-
centrations of 0.25, 0.50, and 1.0 IU/mL. Figure 4A sum-
marizes these results. Confirmation of the absence of a
difference between genders will require testing of larger sam-
ple sizes. Further evaluation with a higher number of volun-
teers will be needed to clarify this point.
c. Clotting times in volunteers aged between 18 and 33
years versus those between 34 and 50 years
The age groups of volunteers evaluated in this study were 18
to 33 years and 34 to 50 years (Figure 4B). No significant
difference were observed between the mean fold prolongations
of Xa CTs of the 2 age groups (P > .05), and results were
similar at all enoxaparin concentrations (0.25, 0.50, and 1.0
IU/mL) evaluated. Confirmation of the absence of a difference
between adult age groups will require testing of larger numbers
of patients over a wider range of ages.
Discussion
The Xa clotting time (TenaCT) test has been designed to pro-
vide a means of assessing the effect of therapeutic LMWH
anticoagulants in individual patients. The impetus for develop-
ing the test is that the variability in the sensitivity of individual
patients to LMWHs is potentially an important clinical variable
that affects both the therapeutic effect and the risk of bleeding.
These variables are known to affect the CTs obtained with
other tests that measure overall coagulation activity.7,17 The
differences in CTs observed within individuals seen in Figure
3 are likely to reflect differences in anticoagulation that create
differences in hemostatic effect. We believe that it is desirable
that the tests used to evaluate dose–response of LMWHs in
general, and enoxaparin in particular, should assess the effect
within the context of plasma samples from individual patients
and not as a standardized measure of the amount of LMWH
present in the plasma sample. The TenaCT achieves this goal
and has been designed to provide CTs that meet the require-
ments of hematology laboratories for rapid, high-volume CTs
tests.
This proof-of-concept study for a Xa-based clotting time test
for enoxaparin was carried out to explore the test reproduci-
bility and to identify factors that may affect its performance.
In vitro experiments carried out using plasma from 20 healthy
volunteers suggested that the TenaCT test was consistently able
to distinguish between the subtherapeutic and therapeutic con-
centrations of enoxaparin. The CTs in the presence of phos-
pholipid, Actin FS, were significantly shorter and less variable
compared to those in its absence, indicating a need to standar-
dize the availability of phospholipid in this rapid CT. Clotting
times were reproducible, were similar among male and female
volunteers, and also among volunteers aged between 18 to 33
years and 34 to 50 years. They were also found to be similar for
individuals on each of 2 occasions. Overall, the present study
provides evidence of reproducibility across a range of factors in
a healthy population.
Experiments with plasma samples, freeze-thawed once,
resulted in significantly shorter CTs compared to the fresh
(unfrozen) plasma samples and were not completed for all 20
volunteers. The shorter CTs may be due to the presence of
microvesicles from trace numbers of frozen-thawed platelets,
or activation of 1 or more clotting factors at low temperature.
The experiments with frozen plasma samples suggest that the
TenaCT test would not work with frozen plasma at the Xa and
Actin FS concentrations used in this study. Additional experi-
ments are needed out to identify the reasons for the differences
and there is a possibility that an entirely different set of Xa
Figure 4. A, Mean fold prolongation in TenaCT using fresh unfrozen plasma of healthy male (red circles) and female (blue squares) volunteers in
the absence or presence of enoxaparin concentrations of 0.25, 0.50, and 1.0 IU/mL. B, Mean fold prolongation in TenaCT using fresh unfrozen
plasma of volunteers aged between 18 and 33 years (red circles) versus those between 34 and 50 years (blue squares) in the absence or presence
of enoxaparin concentrations of 0.25, 0.50, and 1.0 IU/mL.
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Actin FS concentrations may have to be used for frozen plasma.
Significant differences (almost 2-fold) in the prolongation of
CTs were also observed between the 2 plasma samples
obtained from some individuals (n ¼ 4). Biological factors
such as differences in the concentrations of CTs or inhibitors
may have contributed to these differences. Further studies are
needed to identify the cause(s).
Through the in vitro experiments carried out, it was shown
that the TenaCT test has the potential for monitoring enoxa-
parin therapy. The CTs in healthy volunteers were significantly
prolonged with increased enoxaparin concentrations and were
able to distinguish between the concentrations in the range
evaluated in this study (0 vs 0.25, 0.50, and 1 IU/mL). Impor-
tantly, the TenaCT test was able to distinguish between sub-
therapeutic and therapeutic concentrations of enoxaparin.
Currently, none of the alternative factor Xa-activated tests
are used routinely to monitor anticoagulation with LMWHs.
This is an important omission and we believe that the variance
in dose levels and exposure–response of these agents is likely
to be associated with adverse outcomes in some patients. We
propose that patients should be monitored at the beginning of
treatment and where important changes in health status occur
that may impact the level of anticoagulation (eg, significant
changes in renal or liver function, cardiac failure, inflammatory
processes, etc). The magnitude of the differences observed in
the current study provides scope for challenging the view that
monitoring is not required. While patients with renal impair-
ment or liver disease may be obvious candidates for monitor-
ing, confirmation and dose adjustment to standardize
anticoagulation dose have the potential to reduce bleeding in
patients with greater sensitivity to anticoagulation by LMWH
(and indeed potentially other Xa antagonists) or thrombosis as a
result of relative resistance to anticoagulation. Advancement of
this concept of monitoring will require data from further in vivo
studies:
1. evaluation of the prototype test to explore the correla-
tion between the TenaCT, the dose of LMWH, and in
vivo effects: bleeding time and inhibition of thrombosis;
2. more extensive testing of the TenaCT on a larger num-
ber of normal human patients to evaluate the variance in
TenaCT test result with LMWH spiked samples;
3. evaluation of TenaCT test in a range of patient samples:
samples from patients who have received LMWH at
prophylactic and therapeutic dose levels will be needed
to evaluate whether the TenaCT shows values that are
consistent with the intended range of prophylactic or
therapeutic effects, or whether the TenaCT may provide
a useful guide on dose adjustment. This set of studies
may provide evidence for using the TenaCT to control
management by providing a guide for dose adjustment,
rather than using the standard weight-based dosing for
LMWH. It will be particularly relevant in patients with
renal disease, liver disease, inflammatory disorders, and
in cancers and other prothrombotic disorders.
Overall, the proof-of-concept study was considered success-
ful, based on the predefined criteria. This study provided proof-
of-concept for a Xa-based clotting time test that can be used to
detect enoxaparin exposure–response. However, the test is cur-
rently not at a stage to be used clinically. Additional studies are
needed to develop the test for clinical use, such as evaluation
with a higher number of healthy volunteers over a wider age
range, with whole blood, and with frozen plasma samples.
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